Hyderabad, Feb. 24
Aurobindo Pharma Ltd has announced that the US Food Drug Administration (USFDA) has approved its Lisinopril tablets 2.5, 5, 10, 20, 30 and 40 mg.
In a press release here on Friday, Aurobindo said Lisinopril is an angiotensin converting enzyme inhibitor used for controlling blood pressure, treating heart failure and preventing kidney damage in people with hypertension or diabetes. They also benefit patients, who have had heart attacks.
According to the company, the market opportunity for the current approval is around $600 million. The product is manufactured at FDA approved multi purpose plant situated at Bachupally (Unit-III) in the city outskirts.
The company said this cardio vascular system segment, generally referred as `prils', has a turnover of over $3.5 billion in the US market alone and is a key component of the company product portfolio. The Hyderabad-based Aurobindo Pharma has a comprehensive portfolio of over 10 prils in its pipeline and is vertically integrated, the release said.